p38α MAPK 介导 17β-雌二醇抑制人 Lovo 结肠癌细胞中 MMP-2 和 MMP-9 的表达和细胞迁移。
p38α MAPK mediates 17β-estradiol inhibition of MMP-2 and -9 expression and cell migration in human lovo colon cancer cells.
机构信息
Division of Colorectal Surgery, Mackay Memorial Hospital, Taipei, Taiwan.
出版信息
J Cell Physiol. 2012 Nov;227(11):3648-60. doi: 10.1002/jcp.24072.
Epidemiological studies demonstrate that the incidence and mortality rates of colorectal cancer in women are lower than in men. However, it is unknown if 17β-estradiol (E(2)) treatment is sufficient to inhibit cell proliferation and cell migration in human colon cancer cells. Up-regulation of urokinase plasminogen activator (uPA), tissue plasminogen activator (tPA), and matrix metallopeptidases (MMPs) is reported to associate with the development of cancer cell mobility, metastasis, and subsequent malignant tumor. In the present study, we treated human LoVo colon cancer cells with E(2) to explore whether E(2) down-regulates cell proliferation and migration, and to identify the precise molecular and cellular mechanisms behind the down-regulatory responses. Here, we found that E(2) treatment decreased cell proliferation and cell cycle-regulating factors such as cyclin A, cyclin D1 and cyclin E. At the same time, E(2) significantly inhibited cell migration and migration-related factors such as uPA, tPA, MMP-2, and MMP-9. However, E(2) treatment showed no effects on upregulating expression of plasminogen activator inhibitor-1 (PAI-1), tissue inhibitor of metalloproteinase-1, -2, -3, and -4 (TIMP-1, -2, -3, and -4). After administration of inhibitors including QNZ (NFκB inhibitor), LY294002 (Akt activation inhibitor), U0126 (ERK1/2 inhibitor), SB203580 (p38 MAPK inhibitor) or SP600125 (JNK1/2 inhibitor), E(2) -downregulated cell migration and expression of MMP-2 and MMP-9 in LoVo cells is markedly inhibited only by p38 MAPK inhibitors, SB203580. Application of specific target gene siRNA (ERα, ERβ, p38α, and p38β) to LoVo cells further confirmed that p38 MAPK mediates E(2) /ERs inhibition of MMP-2 and -9 expression and cell motility in LoVo cells. Collectively, these results suggest that E(2) treatment down-regulates cell proliferation by modulating the expression of cyclin A, cyclin D1 and cyclin E. E(2) treatment simultaneously impaired cell migration by inhibiting the expression of uPA, tPA, MMP-2, and MMP-9 through E(2) /ERs - p38α MAPK signaling pathway in human LoVo colon cancer cells.
流行病学研究表明,女性结直肠癌的发病率和死亡率低于男性。然而,目前尚不清楚 17β-雌二醇(E(2))治疗是否足以抑制人结肠癌细胞的增殖和细胞迁移。据报道,尿激酶纤溶酶原激活物(uPA)、组织纤溶酶原激活物(tPA)和基质金属蛋白酶(MMPs)的上调与癌细胞迁移、转移和随后的恶性肿瘤的发展有关。在本研究中,我们用 E(2)处理人 LoVo 结肠癌细胞,以探讨 E(2)是否下调细胞增殖和迁移,并确定下调反应背后的确切分子和细胞机制。在这里,我们发现 E(2)处理降低了细胞增殖和细胞周期调节因子,如细胞周期蛋白 A、细胞周期蛋白 D1 和细胞周期蛋白 E。同时,E(2)显著抑制细胞迁移和迁移相关因子,如 uPA、tPA、MMP-2 和 MMP-9。然而,E(2)处理对上调纤溶酶原激活物抑制剂-1(PAI-1)、金属蛋白酶组织抑制剂-1、-2、-3 和 -4(TIMP-1、-2、-3 和 -4)的表达没有影响。在用包括 QNZ(NFκB 抑制剂)、LY294002(Akt 激活抑制剂)、U0126(ERK1/2 抑制剂)、SB203580(p38 MAPK 抑制剂)或 SP600125(JNK1/2 抑制剂)在内的抑制剂处理后,E(2)-下调的细胞迁移和 MMP-2 和 MMP-9 的表达在 LoVo 细胞中明显被 p38 MAPK 抑制剂 SB203580 抑制。将特定靶基因 siRNA(ERα、ERβ、p38α 和 p38β)应用于 LoVo 细胞进一步证实,p38 MAPK 介导 E(2)/ERs 抑制 LoVo 细胞中 MMP-2 和 MMP-9 的表达和细胞迁移。总之,这些结果表明,E(2)通过调节细胞周期蛋白 A、细胞周期蛋白 D1 和细胞周期蛋白 E 的表达来下调细胞增殖。E(2)通过 E(2)/ERs-p38α MAPK 信号通路同时抑制 uPA、tPA、MMP-2 和 MMP-9 的表达,损害人 LoVo 结肠癌细胞的迁移。